Gentian Diagnostics is pleased to announce the release of the new CE marked turbidimetric immunoassay for the simplified quantification of human pancreatic elastase, helping to monitor Pancreatic Exocrine Insufficiency (PEI), the BÜHLMANN fPELA® turbo. This assay is sold through Gentian’s partner BÜHLMANN and Gentian is the sole reagent provider and manufacturer.
BÜHLMANN fPELA® turbo, an immuno turbidimetric faecal pancreatic elastase assay, provides flexible and random-access application on most available clinical chemistry platforms. The assay reduces hands-on time required dramatically and allows the pancreatic elastase results from human stool samples to be reported in a short time.
The same extraction buffer system for pancreatic elastase and faecal calprotectin, Calex® Cap, allows the quantitation of both analytes from the same sample preparation. This helps improve diagnostic efficiency, in addition to clinical advantage, as inflammatory bowel disease (IBD) increases risk for PEI and IBD/PEI symptoms overlap.
Gentian has, in cooperation with BÜHLMANN, delivered the BÜHLMANN fCAL® turbo to the market successfully since 2016. The BÜHLMANN fCAL® turbo is the most automated IVD test system for IBD on the market. It enables laboratories to provide results faster to their clinicians and to run higher test volumes, based on the increasing demand for IBD laboratory diagnostic solutions.
Gentian´s CEO Dr. Hilja Ibert says: As part of the fruitful partnership with BÜHLMANN Laboratories AG, I’m very excited to see the market introduction of the BÜHLMANN fPELA® turbo as a valuable supplement to the existing BÜHLMANN fCAL® turbo.